Daily Newsletter

29 September 2023

Daily Newsletter

29 September 2023

Spring and Eleanor partner to expand SUD support services

Spring Health begun its SUD programme in 2021.

September 29 2023

Spring Health has expanded its substance use disorder (SUD) support services by joining forces with Eleanor Health, a provider of addiction and SUD care.

This partnership aims to offer personalised and evidence-based care to individuals with mental health challenges and SUDs, filling the gap in traditional healthcare systems.

Under this collaboration, Spring Health's integrated mental health solution extends to include comprehensive SUD care, addressing the comorbidity often seen in these cases.

A press statement by Spring Health cites research, which has shown that an integrated approach can improve abstinence rates.

This new offering allows people in certain states to access specialised care for substance addiction through a unified programme.

Spring Health started its SUD programme in 2021 to offer ‘affordable’ care to individuals with different levels of SUD severity, regardless of where they are located.

With its expanding range of SUD services, Spring Health aims to make it easy for patients to receive care within their network.

Eleanor Health specialises in providing evidence-based care for individuals with SUDs and mental health needs, using technology and data-driven insights.

Eleanor Health co-founder and chief medical officer Dr Nzinga Harrison said: “We are delighted to partner with companies like Spring Health that share our mission of driving better outcomes among people struggling with addiction and other mental health conditions.

“Spring Health members in states where Eleanor is available now have access to our whole-person care model, which addresses the physical, mental and psychosocial aspects of addiction to help members achieve and sustain recovery.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Primarily due to COVID-19, the healthcare sector has witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close